Immunogenicity

At Swiss BioQuant, we understand the critical importance of addressing the immunogenicity of large molecule drugs to ensure their long-term safety. With extensive experience in both clinical and non-clinical studies, we employ a comprehensive, multi-tiered approach to effectively detect and characterize immunogenicity. Our methodology includes:

• ADA Prescreening: Initial screening to identify potential anti-drug antibodies.
• Confirmatory Assays: Follow-up tests to confirm the presence of these antibodies.
• ADA Titers: Measuring the titers of antibodies to understand their levels.
• Neutralizing Assays: Anti-drug antibodies can significantly impact your treatment by neutralizing large molecules' binding to targets or inhibiting their enzymatic activity, thereby reducing the drug's pharmacological effectiveness. To detect these neutralizing antibodies, we employ a range of in vitro binding assays (surrogate neutralization assays), enzyme activity assays, and functional cell culture assays..

Our structured approach ensures a thorough evaluation of the ADA response in biopharmaceutical products. By leveraging our extensive experience and advanced techniques, we contribute to the safety and efficacy of these drugs, ultimately supporting better patient outcomes. At Swiss BioQuant, we are committed to providing reliable and accurate immunogenicity assessments, helping you navigate the complexities of biopharmaceutical development with confidence.